This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chattopadhyay, S. Articles by Goldman, I. D. Search for Related Content PubMed PubMed Citation Articles by Chattopadhyay, S. Articles by Goldman, I. D. Related Collections Therapeutics and Targets Therapeutics and Targets: Identification, Validation, and Markers

Reviews

Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications

¹ Departments of Medicine and Molecular Pharmacology, The Albert Einstein College of Medicine Cancer Center, Bronx, New York and ² Department of Pharmacology and Toxicology and The Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia

Requests for reprints: I. David Goldman, Departments of Medicine and Molecular Pharmacology, The Albert Einstein College of Medicine Cancer Center, 1300 Morris Park Avenue, Bronx, NY 10461. Phone: 718-430-2302; Fax: 718-430-8550. E-mail: igoldman{at}aecom.yu.edu

Pemetrexed is a new-generation antifolate, approved for the treatment of mesothelioma and non–small cell lung cancer, currently being evaluated for the treatment of a variety of other solid tumors. This review traces the history of antifolates that led to the development of pemetrexed and describes the unique properties of this agent that distinguish it from other antifolates. These include (a) its very rapid conversion to active polyglutamate derivatives in cells that build to high levels and are retained for long intervals to achieve prolonged and potent inhibition of its major target enzyme thymidylate synthase, (b) its high affinity for three folate transporters, and (c) its marked sensitivity to the level of physiologic folates in cells. The latter results in the unique and paradoxical finding that when transport mediated by the major folate transporter (the reduced folate carrier) is impaired, pemetrexed activity is preserved. This is due to concurrent contraction of competing cellular physiologic folates and utilization of a novel second transport carrier for which pemetrexed has high affinity, recently identified as the proton-coupled folate transporter (PCFT). Laboratory studies are reviewed that raise the possibility of new approaches to the use of folic acid supplementation in clinical regimens with pemetrexed. [Mol Cancer Ther 2007;6(2):404–17]

Note: Current address for S. Chattopadhyay: Dana-Farber Cancer Institute, Boston, Massachussets.

Received 6/12/06; revised 11/ 1/06; accepted 12/ 5/06.

This article has been cited by other articles:

				T. E. Stinchcombe and M. A. Socinski Considerations for Second-Line Therapy of Non-Small Cell Lung Cancer Oncologist, January 1, 2008; 13(suppl_1): 28 - 36. [Abstract] [Full Text] [PDF]

				R. C. Cho, P. D. Cole, K.-J. Sohn, G. Gaisano, R. Croxford, B. A. Kamen, and Y.-I. Kim Effects of folate and folylpolyglutamyl synthase modulation on chemosensitivity of breast cancer cells Mol. Cancer Ther., November 1, 2007; 6(11): 2909 - 2920. [Abstract] [Full Text] [PDF]

				T. Li, Y.-H. Ling, I. D. Goldman, and R. Perez-Soler Schedule-Dependent Cytotoxic Synergism of Pemetrexed and Erlotinib in Human Non-Small Cell Lung Cancer Cells Clin. Cancer Res., June 1, 2007; 13(11): 3413 - 3422. [Abstract] [Full Text] [PDF]